Document:

QuickLinks
 -- Click here to rapidly navigate through this document

 

 
 

Exhibit 10.43    
    

 
 

PROMISSORY NOTE    
    

	$6,521,111	December 31, 2007

        Osiris Therapeutics, Inc., a corporation organized under the laws of the State of Delaware (the "Borrower"), for value received,
hereby promises to pay to Boston Scientific Corporation, or its registered assigns (the "Holder"), the principal sum of Six Million Five Hundred Twenty One Thousand One Hundred Eleven Dollars
($6,521,111) ("Principal Sum"), together with any unpaid accrued interest hereon as set forth below from the date of this Note, upon the terms and conditions specified below. 

        1.    Interest; Payment Terms.    Interest shall accrue on any unpaid balance of the Principal Sum from the date of
the execution hereof at the simple interest rate of eight percent (8%) per annum, based upon a 360 day year. The Principal Sum shall be due and payable in four equal installments paid on
January 2, 2008, April 1, 2008, July 1, 2008, and October 1, 2008. Each installment payment shall include accrued interest on the Principal Sum balance then outstanding.
Upon final payment of all amounts due under this Note, Holder agrees to immediately return the Note to Borrower so that it may be marked "canceled." 

        2.    Events of Default.    If any of the events specified in this Section 2 shall occur (herein individually
referred to as an "Event of Default"), the Holder of the Note may, so long as such condition exists, declare the
entire principal, and unpaid accrued interest hereon, immediately due and payable, by notice in writing to the Borrower: 

        (i)    Default
in the payment of the principal and unpaid accrued interest on this Note when due and payable, if such default is not cured by the Borrower within ten
(10) days after notice of such default is received by Borrower; or 

        (ii)   The
institution by the Borrower of proceedings to be adjudicated as bankrupt or insolvent, or the consent by it to institution of bankruptcy or insolvency proceedings
against it or the filing by it of a petition or answer or consent seeking relief under the federal Bankruptcy Act, or any other applicable federal or state law, or the consent by it to the filing of
any such petition or the appointment of a receiver, liquidator, assignee, trustee or other similar official of the Borrower, or of any substantial part of its property, or the making by it of an
assignment for the benefit of creditors. 

        3.    Prepayment.    The Borrower may at any time prepay in whole or in part the Principal Sum, plus accrued interest
to the date of payment, of this Note, without penalty. 

        4.    Assignment.    The rights and obligations of the Borrower shall not be assignable without the consent of Holder.
Holder may not assign this Note without the consent of the Borrower. If this Note is assigned pursuant to this Section 4, this Note shall be binding upon and benefit the successors, assigns,
heirs, administrators and transferees of the parties. 

        5.    Presentment, Failure to Act.    Presentment for payment, demand, protest and notice of demand, protest and
nonpayment and all other notices, except as specifically required herein, are hereby waived by Borrower. No failure to accelerate the debt evidenced hereby by reason of default hereunder, acceptance
of a past due amount, or indulgences granted from time to time shall be construed (i) as a novation of this Note or as a waiver of the right of Holder thereafter to insist upon strict
compliance with the terms of this Note, or (ii) to prevent the exercise of such right of acceleration or any other right granted hereunder or by the laws of the State of Delaware; and Borrower
hereby expressly waives the benefit of any statute or rule of law or equity now provided, or which may hereafter be provided, which would produce a result contrary to or in conflict with the
foregoing. No extension of the time for the payment of this Note or any installment due hereunder, made by agreement with any person now or hereafter liable for the payment of this Note shall operate
to release, discharge, modify, change or 

affect
the original liability of Borrower under this Note, either in whole or in part unless Holder agrees otherwise in writing. 

        6.    Amendment.    This Note may be amended, waived or modified only upon the written consent of the Borrower and the
Holder. 

        7.    Notices.    Any notice, request or other communication required or permitted hereunder shall be in writing and
shall be deemed to have been duly given if personally delivered or if telegraphed or mailed by registered or certified mail, postage prepaid, at the respective addresses of the parties. Any party
hereto may by notice so given change its address for future notice hereunder. Notice shall conclusively be deemed to have been given when personally delivered or when deposited in the mail or
telegraphed in the manner set forth above and shall be deemed to have been received when delivered. 

        8.    Governing Law.    This Note shall be governed by and construed in accordance with the laws of the State of
Delaware, excluding that body of law relating to conflict of laws. 

        9.    Heading; References.    All headings used herein are used for convenience only and shall not be used to construe
or interpret this Note. Except where otherwise indicated, all references herein to Sections refer to Sections hereof. 

        IN WITNESS WHEREOF, the Borrower has caused this Note to be issued this 31st day of December, 2007. 

	 	BORROWER
	

 	

OSIRIS THERAPEUTICS, INC.
	

 	
By: /s/ C. Randal Mills
 C. Randal Mills, Ph.D.

President and Chief Executive Officer

QuickLinks

Exhibit 10.43

PROMISSORY NOTEExhibit 4.2

 

THIS WARRANT AND THE SHARES OF COMMON STOCK ISSUABLE
UPON THE EXERCISE OF THIS WARRANT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES
ACT OF 1933, AS AMENDED, OR ANY APPLICABLE STATE SECURITIES LAWS, AND MAY NOT
BE SOLD OR TRANSFERRED UNLESS SUCH SALE OR TRANSFER IS IN ACCORDANCE WITH THE
REGISTRATION REQUIREMENTS OF SUCH ACT AND APPLICABLE LAWS OR SOME OTHER
EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF SUCH ACT AND APPLICABLE LAWS IS
AVAILABLE WITH RESPECT THERETO.

 

COMMON
STOCK PURCHASE WARRANT

 

	
  Warrant No. 4

  	
   

  	
  Number
  of Shares 1,000,000

  

 

EXACT Sciences
Corporation

 

Void
after June 26, 2005

 

1.            Issuance. This Warrant is
issued to Laboratory Corporation of America Holdings by EXACT Sciences
Corporation, a Delaware corporation (hereinafter with its successors called the
“Company”).

 

2.            Purchase Price: Number of Shares.
Subject to the terms and conditions hereinafter set forth, the registered
holder of this Warrant (the “Holder”), commencing on the date hereof, is
entitled upon surrender of this Warrant with the subscription form annexed
hereto duly executed, at the office of the Company, 63 Great Road, Maynard,
Massachusetts 01754, or such other office as the Company shall notify the
Holder of in writing, to purchase from the Company at a price per share (the
“Purchase Price”) of $16.09, ONE MILLION (1,000,000) fully paid and
nonassessable shares of Common Stock, $0.01 par value, of the Company (the
“Common Stock”). Until such time as this Warrant is exercised in full or
expires, the Purchase Price and the securities issuable upon exercise of this
Warrant are subject to adjustment as hereinafter provided.

 

3.            Payment of Purchase Price.
The Purchase Price may be paid (i) in cash or by check, (ii) by the surrender
by the Holder to the Company of any promissory notes or other obligations
issued by the Company, with all such notes and obligations so surrendered being
credited against the Purchase Price in an amount equal to the principal amount
thereof plus accrued interest to the date of surrender, or (iii) by any
combination of the foregoing.

 

4.            Partial Exercise. This
Warrant may be exercised in part, and the Holder shall be entitled to receive a
new warrant, which shall be dated as of the date of this Warrant and containing
the same terms as this Warrant, covering the number of shares in respect of
which this Warrant shall not have been exercised.

 

5.            Issuance Date. The person or
persons in whose name or names any certificate representing shares of Common
Stock is issued hereunder shall be deemed to have become the holder of record
of the shares represented thereby as at the close of business on the date this

 

1

 

Warrant is exercised with respect to such shares,
whether or not the transfer books of the Company shall be closed.

 

6.            Expiration Date. This Warrant
shall expire at the close of business on June , 2005 and shall be void
thereafter.

 

7.            Reserved Shares: Valid Issuance.
The Company covenants that it will at all times from and after the date hereof
reserve and keep available such number of its authorized shares of Common
Stock, free from all preemptive or similar rights therein, as will be
sufficient to permit the exercise of this Warrant in full. The Company further
covenants that such shares as may be issued pursuant to the exercise of this
Warrant will, upon issuance, be duly and validly issued, fully paid and
nonassessable and free from all taxes, liens and charges with respect to the
issuance thereof.

 

8.            Dividends. If after the
Original Issue Date (as defined in Section 13 hereof) the Company shall
subdivide the Common Stock, by split-up or otherwise, or combine the Common
Stock, or issue additional shares of Common Stock in payment of a stock
dividend on the Common Stock, the number of shares issuable on the exercise of
this Warrant shall forthwith be proportionately increased in the case of a
subdivision or stock dividend, or proportionately decreased in the case of a
combination, and the Purchase Price shall forthwith be proportionately decreased
in the case of a subdivision or stock dividend, or proportionately increased in
the case of a combination.

 

9.            Sale of Assets and Mergers.
Upon the sale by the Company of all or substantially all of its assets, or the
merger or consolidation of the Company with or into another entity in a
transaction where the shares of the Company’s capital stock outstanding
immediately prior to the closing of such merger or consolidation represent or
are converted into or exchanged for shares that represent less than a majority
of the shares of capital stock of the resulting or surviving entity outstanding
immediately after the closing of such merger or consolidation (each, a
“Business Event”), this Warrant shall expire and thereafter be void. The
Company shall give the Holder of this Warrant thirty (30) days (the “Merger
Exercise Period”) prior written notice of a Business Event. Holder may exercise
this Warrant, in full or in part, during the Merger Exercise Period. Upon the
expiration of the ?Merger Exercise Period, this Warrant shall expire and
thereafter be void.

 

10.          Fractional Shares. In no event
shall any fractional share of Common Stock be issued upon any exercise of this
Warrant. If, upon exercise of this Warrant as an entirety, the Holder would,
except as provided in this Section 10, be entitled to receive a fractional
share of Common Stock, then the Company shall issue the next higher number of
full shares of Common Stock, issuing a full share with respect to such
fractional share.

 

11.          Certificate of Adjustment.
Whenever the Purchase Price is adjusted, as herein provided, the Company shall
promptly deliver to the Holder a certificate setting forth the Purchase Price
after such adjustment and setting forth a brief statement of the facts
requiring such adjustment.

 

2

 

12.          Notices of Record Date. Etc. In
the event of

 

(a)           any taking by the Company of a record
of the holders of any class of securities for the purpose of determining the
holders thereof who are entitled to receive any dividend or other distribution,
or any right to subscribe for, purchase or otherwise acquire any shares of
stock of any class or any other securities or property, or to receive any other
right,

 

(b)           any reclassification of the capital
stock of the Company, capital reorganization of the Company, consolidation or
merger involving the Company, or sale or conveyance of all or substantially all
of its assets, or

 

(c)           any voluntary or involuntary
dissolution, liquidation or winding-up of the Company,

 

then and in each such event the Company will mail or
cause to be mailed to the Holder a notice specifying (i) the date on which any
such record is to be taken for the purpose of such dividend, distribution or
right, and stating the amount and character of such dividend, distribution or
right, or (ii) the date on which any such reclassification, reorganization,
consolidation, merger, sale or conveyance, dissolution, liquidation or
winding-up is to take place, and the time, if any is to be fixed, as of which
the holders of record in respect of such event are to be determined. Such
notice shall be mailed at least 20 days prior to the date specified in such
notice on which any such action is to be taken.

 

13.          Issue Date. This Warrant is
being issued by the Company on June 26, 2002 (the “Original Issue Date”) in
connection with that certain Agreement, dated as of June 26, 2002, between the
Company and Laboratory Corporation of America Holdings.

 

14.          Amendment. The terms of this
Warrant may be amended, modified or waived only with the written consent of the
Company and the Holder of this Warrant.

 

15.          Compliance with the Securities Act.

 

(a)           Compliance with Securities Act.
The Holder of this Warrant, by acceptance hereof, agrees that this Warrant, and
the shares of Common Stock to be issued upon exercise hereof are being acquired
for investment and that such Holder will not offer,, sell or otherwise dispose
of this Warrant, or any shares of Common Stock to be issued upon exercise
hereof except under circumstances which will not result in a violation of the
Securities Act of 1933, as amended (the “Securities Act”) or any applicable
state securities laws. Upon exercise of this Warrant, unless the Common Stock
being acquired is registered under the Securities Act and any applicable state
securities laws or an exemption from such registration is available, the holder
hereof shall confirm in writing that the shares of Common Stock so purchased
(and any shares issued upon conversion thereof) are being acquired for investment
and not with a view toward distribution or resale in violation of the
Securities Act and shall confirm such other matters related thereto as may be
reasonably requested by the Company. This Warrant and all shares of Common
Stock issued upon exercise of this Warrant (unless registered under the

 

3

 

Securities Act and any applicable state securities
laws) shall be stamped or imprinted with a legend in substantially the
following form:

 

THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE
NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AND HAVE BEEN ACQUIRED
FOR INVESTMENT AND NOT WITH A VIEW TO, OR IN CONNECTION WITH, THE SALE OR
DISTRIBUTION THEREOF. NO SUCH SALE OR DISPOSITION MAY BE EFFECTED WITHOUT AN
EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR AN OPINION OF COUNSEL
REASONABLY SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED
UNDER THE SECURITIES ACT OF 1933 AND APPLICABLE STATE SECURITIES LAWS.

 

Said legend shall be removed by the Company, upon the
request of a holder, at such time as the restrictions on the transfer of the
applicable security shall have terminated.

 

(b)          In addition, in connection with the
issuance of this Warrant, the Holder specifically represents to the Company by
acceptance of this Warrant as follows:

 

(i)            The Holder is aware of the Company’s
business affairs and financial condition, and has acquired information about
the Company sufficient to reach an informed and knowledgeable decision to
acquire this Warrant. The Holder is acquiring this Warrant for its own account
for investment purposes only and not with a view to, or for the resale in
connection with, any “distribution” thereof in violation of the Securities Act
or applicable state securities laws.

 

(ii)           The Holder understands that this
Warrant has not been registered under the Securities Act in reliance upon a
specific exemption therefrom, which exemption depends upon, among other things,
the bona fide nature of the Holder’s investment intent as expressed herein.

 

(iii)          The Holder further understands that
this Warrant must be held indefinitely unless subsequently registered under the
Securities Act and qualified under any applicable state securities laws, or
unless exemptions from registration and qualification are otherwise available.
The holder is aware of the provisions of Rule 144, promulgated under the
Securities Act.

 

16.          Warrant Register; Transfers, Etc.

 

(a)           Subject to the provisions of Section
15 hereto, this Warrant and all rights hereunder are transferable (but only
with all related obligations) with the prior written consent of the Company,
and upon surrender of the Warrant with a properly executed assignment (in the
form attached hereto) at the principal office of the Company, or at such other
office or agency as the Company may designate.

 

(b)           Each holder of this Warrant
acknowledges that this Warrant and the Common Stock of the Company issuable
upon exercise hereof have not been registered under the

 

4

 

Securities Act, and agrees not to sell, pledge,
distribute, offer for sale, transfer or otherwise dispose of this Warrant or
any Common Stock issued upon its exercise in the absence of (i) an effective
registration statement under the Securities Act as to this Warrant or such
Common Stock and registration or qualification of this Warrant or such Common
Stock under any applicable blue sky or state securities law then in effect, or
(ii) an opinion of counsel, reasonably satisfactory to the Company, that such
registration and qualification are not required.

 

(c)           Until any transfer of this Warrant is
made in the warrant register, the Company may treat the Holder of this Warrant
as the absolute owner hereof for all purposes; provided, however,
that if and when this Warrant is properly assigned in accordance with this
Section 16, the Company may (but shall not be required to) treat the bearer
hereof as the absolute owner hereof for all purposes, notwithstanding any
notice to the contrary. Except as otherwise expressly provided herein, the
provisions hereof shall inure to the benefit of, and be binding upon, the
successors, assigns, heirs, executors and administrators of the parties hereto,
as may be appropriate.

 

(d)           The Company will maintain a register containing
the names and addresses of the registered holders of this Warrant. Any
registered holder may change such registered holder’s address as shown on the
warrant register by written notice to the Company requesting such change.

 

17.          No Impairment. The Company will
not, by amendment of its Certificate of Incorporation or through any
reclassification, capital reorganization, consolidation, merger, sale or
conveyance of assets, dissolution, liquidation, issue or sale of securities or
any other voluntary action, avoid or seek to avoid the observance or
performance of any of the terms of this Warrant, but will at all times in good
faith assist in the carrying out of all such terms and in the taking of all
such action as may be necessary or appropriate in order to protect the rights
of the Holder.

 

18.          Registration Rights.

 

(a)           Whenever the Company proposes to file
a registration statement with the Securities and Exchange Commission for a
public offering and sale of securities of the Company (other than a registration
statement on Form S8 or Form S4, or their successors, or any other form for a
limited purpose, or any registration statement covering only securities
proposed to be issued in exchange for securities or assets of another
corporation) (a “Registration Statement”), it will, prior to such filing, give
written notice to the Holder of its intention to do so and, upon the written
request of the Holder given within 30 days after the Company provides such
notice, the Company shall use commercially reasonable efforts to register under
the Securities Act pursuant to the Registration Statement all shares of Common
Stock issued or issuable upon conversion of the Warrant (“Registrable Shares”)
for which the Holder has requested registration; provided that the Company
shall have the right to postpone or withdraw any registration effected pursuant
to this Section 18 without obligation to the Holder; and provided further that
the Company shall have no obligation to register Registrable Shares which have
already been registered under the Securities Act pursuant to an effective
registration statement or are owned by a Holder who could immediately sell all
of such Registrable Shares publicly pursuant to Rule 144 under the Securities
Act.

 

5

 

(b)           In connection with any offering under
Section 18(a) involving an underwriting, the Company shall include in such
offering all the Registrable Shares specified in a written request or requests,
mailed by the Holder within 30 days of receipt of such written notice from the
Company, provided that the Company may limit, to the extent so advised by the
underwriters as a result of market conditions, the amount of Registrable Shares
to be included in the registration by the Holder to an amount not less than one
third of the total number of securities included in the offering. If the number
of Registrable Shares to be included in the underwriting in accordance with the
foregoing is less than the total number of Registrable Shares which the Holder
has requested to be included, then the Company may include all securities
proposed to be registered by the Company to be sold for its own account and the
Holder shall participate in the underwriting pro rata based upon its total
ownership of shares of Common Stock of the Company, together with any
additional holders of shares of the Company’s capital stock who has requested
registration of any or all of such holder’s shares pursuant to and in
accordance with a grant of registration rights by the Company (a “Selling
Securityholder”). If any Selling Securityholder would thus be entitled to
include more shares than such Selling Securityholder requested to be
registered, the excess shall be allocated among other requesting Selling
Securityholders pro rata based upon their total ownership of shares.

 

(c)           If at any time (i) the Holder
requests that the, Company file a Registration Statement on Form S3 or any
successor thereto for a public offering of all or any portion of the
Registrable Shares with an aggregate proposed offering price of at least
$500,000, and (ii) the Company is a registrant entitled to use Form S3 or any
successor thereto to register such shares, then the Company shall use its
reasonable best efforts at its own expense to file a Registration Statement on
Form S3 or any successor thereto, for public sale in accordance with the method
of disposition specified in such notice, the number of Registrable Shares
specified in such notice; provided, however, that the Company shall have no
obligation to register Registrable Shares which have already been registered
under the Securities Act pursuant to an effective registration statement or are
owned by a Holder who could immediately sell all of such Registrable Shares
publicly pursuant to Rule 144 under the Securities Act. The Company shall be
entitled to include in any Registration Statement referred to in this Section
18(c) shares of Common Stock to be sold by the Company for its own account or
for the account of a Selling Securityholder, except as and to the extent that,
in the opinion of the managing underwriter, if any, such inclusion would
adversely affect the marketing of the Registrable Shares to be sold.
Notwithstanding anything to the contrary in this Section 18(c), the Company
shall not be required to effect more than one registration pursuant to this
Section 18(c) in any 12 month period.

 

(d)           A Holder proposing to distribute its
securities in an offering under this Section 18 involving an underwriting shall
(together with the Company and other shareholders of securities distributing
their shares through such underwriting) enter into an underwriting agreement in
customary form with the underwriter or underwriters selected for the
underwriting.

 

(e)           The Company shall not be obligated to
register, pursuant to this Section 18, the Registrable Shares of any Holder who
fails to provide promptly to the Company such information as the Company may
reasonable request at any time to enable the Company to

 

6

 

comply with any applicable law or regulation or to
facilitate preparation of the Registration Statement.

 

(f)            In connection with any public
offering of equity securities of the Company, the Holder agrees not to sell,
pledge, hypothecate, hedge, transfer or otherwise dispose of, or grant any
option or purchase right with respect to, any shares of capital stock of the
Company then owned by the Holder and not otherwise offered in the public
offering, or engage in any short sale, hedging transaction or other derivative
security transaction involving the Registrable Shares or other shares of Common
Stock of the Company held by the Holder, for such period of time commencing ten
(10) days prior to the proposed effective date of such public offering and
until 180 days following the effective date of such public offering.

 

(g)           All expenses incurred by the Company
in complying with this Section 18, including, all registration and filing fees,
printing expenses, fees and disbursements of counsel and independent public accountants
for the Company, fees and expenses incurred in connection with complying with
state securities or “blue sky” laws, fees of the National Association of
Securities Dealers, Inc., transfer taxes, fees of transfer agents and
registrars and costs of insurance, but excluding any Selling Expenses, are
called “Registration Expenses”. All underwriting discounts and selling
commissions applicable to the sale of Restricted Stock and fees and
disbursements of counsel for the sellers of the Registrable Shares are called
“Selling Expenses”. The Company will pay all Registration Expenses in
connection with each registration statement under this Section 18. All Selling
Expenses in connection with each registration statement under this Section 18
shall be borne by the participating sellers in proportion to the number of
shares sold by each, or by such participating sellers other than the Company
(except to the extent the Company shall be a seller) as they may agree.

 

19.          Rule 144 Reporting. With a view
to making available the benefits of certain rules and regulations of the
Securities and Exchange Commission which may at any time permit the sale of the
Registrable Shares to the public without registration, the Company agrees to:

 

(a)           make and keep public information available,
as those terms are understood and defined in Rule 144 under the Securities Act;

 

(b)           use commercially reasonable efforts
to file with the Securities and Exchange Commission in a timely manner all
reports and other documents required of the Company under the Securities Act
and the Exchange Act of 1934, as amended (the “Exchange Act”); and

 

(c)           furnish to each holder of Registrable
Shares forthwith upon request a written statement by the Company as to its
compliance with the reporting requirements of such Rule 144 and of the
Securities Act and the Exchange Act, a copy of the most recent annual or
quarterly report of the Company, and such other reports and documents so filed
by the Company as such holder may reasonably request in availing itself of any
rule or regulation of the Securities and Exchange Commission allowing such
holder to sell any Registrable Shares without registration.

 

7

 

20.          Governing Law. The provisions
and terms of this Warrant shall be governed by and construed in accordance with
the internal laws of the Commonwealth of Massachusetts.

 

21.          Successors and Assign. This
Warrant shall be binding upon the Company’s successors and assigns and shall
inure to the benefit of the Holder’s successors, legal representatives and
permitted assigns.

 

22.          Business Days. If the last or
appointed day for the taking of any action required or the expiration of any
right granted herein shall be a Saturday or Sunday or a legal holiday in the
Commonwealth of Massachusetts, then such action may be taken or right may be
exercised on the next succeeding day which is not a Saturday or Sunday or such
a legal holiday.

 

23.          Shareholder Rite. Except as set
forth herein, no holder of this Warrant, as such, shall be entitled to vote
upon any matter submitted to shareholders at any meeting thereof, or to receive
notice of meetings, or be deemed the holder of Common Stock until this Warrant
shall have been exercised and the Shares purchasable upon such exercise shall
have become deliverable, as provided herein.

 

[Remainder of Page
Intentionally Left Blank]

 

8

 

	
  Dated: June 26, 2002

  	
   

  	
  EXACT SCIENCES
  CORPORATION

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
  (Corporate Seal)

  	
   

  	
  By:

  	
   /s/ Don M.
  Hardison

  
	
   

  	
   

  	
   

  	
  Name:

  
	
   

  	
   

  	
   

  	
  Title:

  
	
   

  	
   

  	
   

  
	
  Attest:

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
   /s/ John A.
  McCarthy, Jr.

  	
   

  	
   

  
	
   

  	
   

  	
   

  

 

9

 

Subscription

 

	
  To:

  	
   

  	
   

  	
  Date:

  	
   

  

 

The undersigned hereby
subscribes for the shares of Common Stock covered by this Warrant. The
certificates) for such shares shall be issued in the name of the undersigned or
as otherwise indicated below:

 

 

	
   

  	
   

  
	
   

  	
  Signature

  
	
   

  	
   

  
	
   

  	
   

  
	
   

  	
  Name for Registration

  
	
   

  	
   

  
	
   

  	
   

  
	
   

  	
  Mailing Address

  

 

10

 

Assignment

 

For value received                                                         hereby sells, 

 

assigns and
transfers unto 

 

 

Please print or
typewrite name and address of Assignee

 

 

the within
Warrant, and does hereby irrevocably constitute and appoint

 

                                                                    its
attorney to transfer the within Warrant on the books of the 

 

within named
Company with full power of substitution on the premises.

 

	
  Dated:

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
  In the Presence of:

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  

 

11

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00138-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00138-of-00352.parquet"}]]